Marc S. Raab

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki et al. · New England Journal of Medicine · 2018 · 535 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Blood · 2018 · 495 citations · Full text

Medicine, Molecular Biology, Oncology +12

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Leukemia · 2018 · 453 citations · Full text

Medicine, Genetics, Molecular Genetics +17